High dose valacyclovir for cytomegalovirus prophylaxis following allogeneic hematopoietic cell transplantation.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）
Abstract
Prospective evaluation of valacyclovir 1 g three times daily for viral prophylaxis following allogeneic HCT is warranted. Due to valacyclovir's favorable toxicity profile and affordable cost, it has the potential to benefit patients on a broad scale as an option for CMV prophylaxis.
MoreTranslated text
Key words
Cytomegalovirus,allogeneic transplantation,hematopoietic cell transplantation,valacyclovir
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined